Compounding Pharmacies' Lawsuit Against FDA Will Continue
Compounding Pharmacies' Lawsuit Against FDA Will Continue
The US District Court for the Western District of Texas (Midland, TX) has ruled that a lawsuit against the US Food and Drug Administration will proceed, despite a request from FDA to drop the case.
A coalition of 10 compounding pharmacies hit FDA with a lawsuit for engaging in “unlawful” inspections of state-regulated pharmacies. At the center of the lawsuit is FDA’s 2003 compliance policy guideline (CPG 7125.40), which prohibits the compounding of drugs from bulk ingredients. The agency has since inspected several compounding pharmacies to enforce the guidelines.
The pharmacies petitioned the court to allow them to continue using compounding methods without FDA considering them a manufacturer or requiring them to meet the agency’s manufacturing guidelines. The coalition alleges that federal law prohibits FDA from inspecting state-regulated pharmacies and that the agency is exercising jurisdiction without the authority to do so.
–Kaylynn Chiarello
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
